Judge Puts the Brakes on Melinta Therapeutics Sale Process
A bankruptcy judge has temporarily halted biotechnology company Melinta Therapeutics Inc.’s proposed chapter 11 sale plan, which calls for a potential takeover deal with the company’s senior lender, health-care investment firm Deerfield Management Co., WSJ Pro Bankruptcy reported. Judge Laurie Selber Silverstein of the U.S. Bankruptcy Court in Wilmington, Del., instructed the antibiotics maker to rework its proposed bidding and sale process of its assets to allow more time to look for other competitive bids. She directed lawyers for Melinta and creditors to consider extending the bid deadline and opening up the process to accept rival bids. The condensed time frame and restrictive bidding procedures concerned the judge because they could prevent someone else from bidding, she said at a six-hour hearing Tuesday. Judge Silverstein’s request for Melinta to push back its sale timeline came after several objections from the federal government’s bankruptcy watchdog and some creditors. The bid deadline had initially been set for Feb. 10 and an auction for Feb. 13. The U.S. trustee and Vatera Healthcare Partners LLC, a venture-capital and private-equity investment arm of Vatera Holdings LLC and one of Melinta’s largest creditors, had balked at terms of the deal that would allow Deerfield to proceed with a $140 million credit bid.
